

ASPIRE BioNEST signs strategic MoU with Indian Immunologicals to advance One Health Innovation

27 March 2026 | News

Startups to benefit from Indian Immunologicals' technical mentorship and domain expertise



ASPIRE BioNEST, a premier life sciences incubation centre at the University of Hyderabad, has signed a strategic Memorandum of Understanding (MoU) with Indian Immunologicals Ltd. (IIL), a leading vaccine-focused biotechnology company, to advance innovation under the One Health framework.

As part of this engagement, Dr K.Anand Kumar, MD, IIL visited ASPIRE-BioNEST and interacted with incubated startups, sharing insights on product development, regulatory pathways, and scale-up strategies, thereby providing startups with valuable industry perspective.

This partnership represents an important step towards strengthening India's biotechnology innovation ecosystem, with a strong emphasis on integrated human, animal, and environmental health under the One Health framework.

Under the MoU, startups will benefit from IIL's technical mentorship and domain expertise, along with access on a mutually agreed basis to advanced process development and analytical facilities, including capabilities relevant to viral and bacterial vaccine development. Opportunities to leverage IIL's CDMO capabilities for scale-up and manufacturing readiness will also be explored.

Dr. K.Anand Kumar stated that Indian Immunologicals Ltd. will actively support startups at ASPIRE-BioNEST by extending its

full spectrum of expertise across the product development lifecycle—from early-stage research and validation to scale-up, regulatory pathways, and commercialisation.